Holen Sie sich die Stockscreener-App
5.64
6.47%
-0.39
Handel nachbörslich:
5.75
0.11
+1.95%
Schlusskurs vom Vortag:
$6.03
Offen:
$6.03
24-Stunden-Volumen:
1.74M
Relative Volume:
0.72
Marktkapitalisierung:
$1.15B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-17.09
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
-12.56%
1M Leistung:
-2.93%
6M Leistung:
+168.57%
1J Leistung:
+83.71%
1-Tages-Spanne:
$5.565
$6.03
1-Wochen-Bereich:
$5.565
$6.50
52-Wochen-Spanne:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.64 | 1.23B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease - MyChesCo
Savara (NASDAQ:SVRA) Shares Down 5.1%Should You Sell? - MarketBeat
Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December - MarketBeat
Death Cross: Is Savara Inc stock a defensive play in 2025Market Growth Summary & Safe Capital Growth Plans - moha.gov.vn
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo
With 37% Ownership in Savara Inc. (NASDAQ:SVRA), Institutional Investors Have a Lot Riding on the Business - 富途牛牛
Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA - MarketBeat
Gap Down: Is Savara Inc YB4P stock a buy for dividend portfolios2025 Trade Ideas & AI Based Buy and Sell Signals - moha.gov.vn
How Savara Inc. stock reacts to Fed rate cutsSector Performance Review & Your Free Entry to Smart Investing Starts Here - bollywoodhelpline.com
Savara price target raised to $10 from $8 at HC Wainwright - MSN
Savara Inc. ticks higher amid takeover speculation - MSN
Market Review: How MTEN stock performs in high volatility marketsMarket Trend Report & Accurate Intraday Trade Tips - moha.gov.vn
What is HC Wainwright's Forecast for Savara FY2027 Earnings? - MarketBeat
Savara (SVRA) Stock Price, Quote, News & History - Benzinga
FY2029 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission By Investing.com - Investing.com South Africa
Savara (SVRA) Receives Revised Buy Rating from HC Wainwright & C - GuruFocus
Savara stock price target raised to $10 from $8 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission - Investing.com Nigeria
Savara stock price target raised to $10 from $8 at H.C. Wainwright - Investing.com Nigeria
How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st
Savara resubmits BLA for rare lung disease treatment with new manufacturer - Investing.com Nigeria
Savara Resubmits Molbreevi Application to FDA for Rare Lung Disease - marketscreener.com
Savara (SVRA) Resubmits Molbreevi BLA to FDA for Autoimmune PAP Treatment - GuruFocus
Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway - MSN
Savara resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi - marketscreener.com
Savara resubmits BLA for rare lung disease treatment with new manufacturer By Investing.com - Investing.com South Africa
Savara : Corporate Presentation - marketscreener.com
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance
Savara Inc.(NasdaqGS: SVRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Savara Locks In Long-Term Europe Protection for Rare Lung Drug MOLBREEVI - MyChesCo
Why Savara Inc. stock could rally in 2025Market Volume Summary & Daily Technical Forecast Reports - Улправда
How big funds are accumulating Savara Inc. (YB4P) stockOil Prices & Safe Capital Growth Stock Tips - Улправда
Why Savara Inc. (YB4P) stock could outperform next yearJuly 2025 Institutional & Entry Point Confirmation Signals - Улправда
Aug Closing: Why Savara Inc. stock could rally in 2025Profit Target & Safe Capital Allocation Plans - Улправда
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
Will Savara Inc. stock outperform tech sector in 2025Earnings Risk Summary & Real-Time Volume Trigger Notifications - DonanımHaber
Can Savara Inc. stock beat market expectations this quarterJuly 2025 Price Swings & AI Driven Price Forecasts - DonanımHaber
How Savara Inc. stock benefits from global expansionGlobal Markets & Growth Focused Entry Point Reports - DonanımHaber
How Savara Inc. stock performs in weak economyJuly 2025 Decliners & Real-Time Volume Analysis Alerts - DonanımHaber
Will Savara Inc. stock benefit from sector rotation2025 Dividend Review & Technical Entry and Exit Tips - Улправда
Wells Fargo Raises Price Target for Savara (SVRA) to $9.00 | SVR - GuruFocus
Savara (NASDAQ:SVRA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences - MSN
Breakouts Watch: Will Savara Inc. stock benefit from sector rotationJuly 2025 Volume & Weekly High Return Stock Forecasts - Улправда
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference - The Joplin Globe
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):